【レポートの概要（一部）】
1. Report Overview
1.1 Top Stem Cell Technology Companies: Overview
1.2 Global Stem Cell Technology Market Segmentation
1.3 Why You Should Read This Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
1.11 Glossary
2. The Global Stem Cell Technology and Applications Market 2015-2025
2.1 The Stem Cell Technologies and Applications Market in 2014
2.2 Non-therapeutic Applications Constitutes the Largest Segment in 2014, Oncology the Largest Therapeutic Area
2.3 Global Stem Cell Technology and Applications Market: Regional Breakdown, 2014
2.4 Global Stem Cell Technology and Applications Market Forecast 2015-2025
2.5 Fast Growth Owing to Therapeutic Potential, Drug Screening and Emerging Markets
2.6 Global Stem Cell Technology and Applications Market Forecast by Therapeutic Segment 2015-2025
2.7 Therapeutic Applications to Overtake Non-Therapeutic Applications in 2020
2.8 How Will Market Shares for the Different Segments Within the Stem Cells Market Change from 2014-2025?
2.9 Drivers and Restraints for the Stem Cell Technology and Applications Market, 2015-2025
3. Leading US Stem Cell Technology Companies
3.1 Regulation, Patentability and ‘Homologous Use’ in the US
3.1.1 Embryonic Stem Cell Research Remains Controversial in the US
3.2 Osiris Therapeutics
3.2.1 Developed and then Sold the Rights to Osteocel and Prochymal
3.2.2 Grafix Reports Impressive Clinical Trial Results, Now Available in More Sizes
3.2.2.1 Is Grafix Really a ‘Stem Cell Product’?
3.2.3 OvationOS: Stem Cell Product for Regeneration of Bone Tissue
3.2.4 Cartiform – Launched to Address a Potential $500m Market
3.2.4.1 Partnership with Arthrex for the Commercialisation and Development of Cartiform
3.2.5 Osiris Therapeutics Stem Cell Revenue Forecast 2014-2025
3.2.6 Osiris Therapeutics: Optimistic Outlook for that Leading Stem Cell Company
3.3 NeoStem: Generating Revenue through Services whilst Developing Stem Cell Therapies
3.3.1 Growth Through Acquisitions – Including PCT, Amorcyte, Athelos and California Stem Cell Inc.
3.3.2 NBS10 – Lead Candidate in NeoStem’s Ischaemic Repair Programme
3.3.2.1 NBS10 Shows Positive Initial Results From 2014 Phase II Clinical Trial
3.3.3 VSEL Technology: Potential to Treat Ocular Diseases and Chronic Wounds?
3.3.4 NeoStem Revenues 2011-2014
3.3.5 NeoStem Outlook in Summary: NBS10 Could Cater to 160,000 Patients a Year
3.4 Orthofix – Two Orthobiologic Products Already on the Market
3.4.1 Trinity Evolution and Trinity Elite – Over 90,000 Procedures to Date
3.4.1.1 Trinity Elite and Trinity Evolution: Revenue Forecast 2014-2025
3.4.2 Orthofix Outlook in Summary: High Revenues from Trinity Products but Will Have to Demonstrate Efficacy
3.5 NuVasive: Owns the Leading Stem Cell Orthobiologic
3.5.1 Osteocel to Osteocel Plus: Changes and Challenges
3.5.1.1 Osteocel Plus: The Leading Stem Cell Orthobiologic
3.5.1.2 Osteocel Plus: Is it Better than Autograft?
3.5.1.3 Osteocel Plus: Revenue Forecast 2015-2025
3.5.2 NuVasive Outlook in Summary: Osteocel Plus Revenues Will Continue to Grow, Although will Face Increased Competition in Coming Years
3.6 AlloSource: Non-Profit which Markets AlloStem and Processes Osteocel for NuVasive
3.6.1 AlloStem: Stem Cell Bone Growth Substitute
3.7 RTI Surgical: Company adds to their Orthobiologic Portfolio with Map3
3.7.1 Map3: RTI Surgical is Competing with Established Players like NuVasive and Orthofix
3.8 Vericel Corporation (Formerly Aastrom Biosciences)
3.8.1 Ixmyelocel-T
3.8.2 Vericel Focusing on Dilated Cardiomyopathy (DCM) and Away From CLI
3.8.3 Ixmyelocel-T: Orphan Drug Designation and Undergoing Phase 2b Trial for DCM and Phase 1/2 for Craniofacial Reconstruction
3.8.4 Vericel Corporation Revenues 2011-2013
3.8.5 Vericel Corporation: Outlook in Summary
3.9 Bioheart
3.9.1 MyoCell: Autologous ‘Muscle Stem Cell’ Therapy
3.9.1.1 MyoCell: Undergoing Phase 2/3 (‘MARVEL’) Trial
3.9.1.2 MyoCell: MIRROR Phase 3 Trial Progress
3.9.2 MyoCell SDF-1: Improved Version of MyoCell
3.9.2.1 MyoCell SDF-1 Phase 1 Trial (REGEN) Trial
3.9.3 Adipocell for CLI in Phase 1/2, and Being Investigated for RI and Degenerative Disc Disease
3.9.3.1 Adipocell: Also Being Investigated for DDD, COPD and Dry Macular Degeneration
3.9.4 Bioheart Revenues 2010-2013
3.9.5 Bioheart: Outlook in Summary
3.10 Neuralstem
3.10.1 NSI-566 Completes Phase 2 for ALS, Long-Term Follow-Up Data is Promising
3.10.2 NSI-566 for Chronic Spinal Cord Injury: Phase 1, expected to Begin Phase 1/2 for Acute Spinal Cord Injury Q1 2015
3.10.3 NSI-566 for Ischaemic Stroke: Phase 1/2 Trials Underway in China
3.10.4 Neuralstem: Preclinical Investigation for 11 Other Indications
3.10.5 Neuralstem Revenues 2010-2013
3.10.6 Neuralstem Outlook in Summary: Aiming to Treat a Wide Range of Conditions – Potential Revenues are Huge
3.11 Ocata Therapeutics (Formerly Advanced Cell Technology)
3.11.1 Broad Intellectual Property Portfolio and Recent Funding from Lincoln Park Capital
3.11.2 MA09-hRPE in Two Phase 1/2 Trials for Stargardt’s Macular Degeneration
3.11.2.1 Early Signals of Efficacy?
3.11.3 MA09-hRPE: Phase 2 in Dry Age Related Macular Degeneration and Phase 1/2 for Myopic Macular Degeneration
3.11.4 Ocata Therapeutics Revenues, 2011-2013
3.11.5 Ocata Therapeutics: Outlook in Summary
3.12 From Procedures to Products: Cord Blood Stem Cell Approvals
3.12.1 Hemacord by New York Blood Center
3.12.2 HPC, Cord Blood by ClinImmune and University of Colorado Cord Blood Bank
3.12.3 Ducord by Duke University School of Medicine
3.12.4 Allocord by SSM Cardinal Glennon Children’s Medical Center
3.12.5 HPC, Cord Blood BLA 125432 by LifeSouth Community Blood Centers
4. Leading Asia-Pacific Stem Cell Technology Companies
4.1 South Korea: Moving Rapidly to Commercialisation for MSC Therapies – but is it Exercising Enough Caution?
4.2 India: An Emerging Stem Cell Industry
4.3 Japan: Has Been Less Active than other Asian Countries in hESC Research
4.4 China: Liberal Laws for Stem Cell Research
4.5 Mesoblast: Australian Company with Extensive Product Pipeline
4.5.1 Purchase of Prochymal from Osiris and Partnership with Lonza
4.5.2 Prochymal: World’s First Approved Stem Cell Drug Outside of South Korea – Currently has Limited Market Access
4.5.2.1 Prochymal: Culture Expanded and Able to Treat GvHD
4.5.2.2 Mesoblast also Evaluating Prochymal for Treatment of Crohn’s Disease
4.5.2.3 Prochyma: Revenue Forecast, 2015-2025
4.5.3 Mesoblast Evaluating MPCs for Treatment of Diabetes in Phase 2
4.5.4 Mesoblast Evaluating MPCs for Treatment of Rheumatoid Arthritis in Phase 2
4.5.5 CEP-41750 in Phase 3 for Congestive Heart Failure
4.5.6 Phase 2 Trial of MPCs in Acute Myocardial Infarction
4.5.7 Promising Preclinical Findings in Ischaemic Stroke
4.5.8 Phase 2 Trials of MPCs in Intervertebral Disc Repair and Spinal Fusion
4.5.9 Phase 3 Trial in Haematological Malignancies
4.5.10 Phase 2 in Wet AMD, Preclinical In Neurology
4.5.11 Mesoblast Revenues, 2012-2014
4.5.12 Mesoblast Outlook in Summary: Large and Diversified Development Pipeline
4.6 Reliance Life Sciences: Indian Company with Stem Cell Therapies Already on the Market
4.6.1 CardioRel – Already Available in the Indian Market
4.6.1.1 CardioRel: Revenue Forecast, 2015-2025
4.6.2 ReliNethra – The First Stem Cell Therapy in India
4.6.3 ReliNethra C and ReliCord
4.6.4 Reliance Life Sciences: Outlook in Summary – First out of the Gate in the Indian Market, but What about Global Reach?
4.7 Anterogen: South Korean Company with Products Already on the Market
4.7.1 Cupistem: World’s First Approved Stem Cell Product Derived from Adipose Tissue
4.7.2 Queencell: Stromal Vascular Fraction containing Autologous MSCs, and a Phase 1/2 Trial for Treatment of Tennis Elbow
4.7.3 Anterogen: Quick to Market, but How Much Remaining Potential?
4.8 Pharmicell
4.8.1 Hearticellgram-AMI, One of the First Approved Cardiovascular Stem Cell Treatments
4.8.1.1 Hearticellgram-AMI: Potential Difficulty Getting Approval in Markets outside South Korea?
4.8.1.2 Hearticellgram-AMI: Revenue Forecast, 2015-2025
4.8.2 Cerecellgram for Stroke in Phase 3 and Cerecellgram for Spinal Cord Injuries in Phase 2/3: Both Expected to Finish Early 2016
4.8.3 Immunocellgram for Cancers and Lungcellgram for Pulmonary Fibrosis: Both in Preclinical Stages
4.8.4 Cellgram for Erectile Dysfunction – Undergoing Phase 1, and a Treatment for Multiple System Atrophy, Completed Phase 1
4.8.5 Livercellgram for Hepatic Failure: Phase 2 Completed January 2015
4.8.6 Pharmicell Outlook in Summary: Quick to Market and Large Pipeline, but Needs to Make a Push to Expand out of South Korea
4.9 MEDIPOST
4.9.1 Cartistem: ‘World’s First Allogeneic Stem Cell Drug’
4.9.1.1 Cartistem: Revenue Forecast, 2015-2025
4.9.2 Neurostem: Undergoing Phase 1/2a Study
4.9.3 Pneumostem: Undergoing Phase 1 in Intraventricular Haemorrhage and Phase 2 in Bronchial Pulmonary Dysplasia
4.9.4 MEDIPOST Outlook in Summary: One Stem Cell Therapy Already on the Market and South Korea’s Largest Cord Blood Bank
4.10 Stempeutics
4.10.1 Stempeucel: Phase 2 Trials for CLI, Liver Cirrhosis and OA
4.10.2 Stempeucel for Various Other Indications
4.10.3 Alliance with Cipla
4.10.4 Stempeutics Outlook in Summary: Using Stempeucel to Treat a Range of Disorders
5. Leading European Stem Cell Technology Companies
5.1 Regulation in Europe
5.2 UK Leads in European Stem Cell R&D
5.3 TiGenix: Proprietary Technology Platform and Three Stem Cell Products in Development
5.3.1 ChondroCelect Already on the Market
5.3.2 eASC Technology Platform
5.3.3 Cx601: European Phase 3 Data Expected in July 2015
5.3.3.1 Cx601: TiGenix Partners with Lonza, and Will Have Another Phase 3 Trial in the US
5.3.4 Cx611: Phase 2 for Rheumatoid Arthritis, and Phase 1 for Severe Sepsis
5.3.5 Cx621 – Positive Results from Phase 1 Trial
5.3.6 TiGenix Outlook in Summary: Cx601 Reaching End of Development and Represents the Company’s Greatest Strength
5.4 Cardio3 BioSciences: Develops Regenerative Therapies for Cardiovascular Diseases
5.4.1 Cardio3’s Proprietary Cardiopoiesis Technology Platform – Can be Applied to Various Stem Cell Sources
5.4.2 C-Cure: Stem Cell Therapy for the Treatment of Heart Failure
5.4.2.1 Phase 3 Trial Begins Amid Controversy
5.4.3 Cardio3 Outlook in Summary: Targeting a Therapeutic Area with High Unmet Need
5.5 Apceth
5.5.1 Proprietary Technology Platform Delivers Therapeutic Genes Directly to the Target
5.5.2 Agenmestencel-T for the Treatment of GI-tract Adenocarcinoma
5.5.3 Alecmestencel-T for the Treatment of PAOD/CLI
5.5.4 Alecmestencel-L for the Treatment of GvHD
5.5.5 Apceth Outlook in Summary: A Variety of Industry Firsts and Positive Outlook, Although Pipeline is in Early Stages
5.6 ReNeuron: Targeting Areas of Unmet Medical Need
5.6.1 CTX Neural Cell Line: Provides Technical and Competitive Advantages
5.6.1.1 CTX for Stroke: Interim Results from P
ISCES Study Show Positive Results
5.6.1.2 CTX for Stroke: Currently Undergoing Phase 2 Study
5.6.1.3 CTX for Critical Limb Ischaemia: Undergoing Phase 1, will be Completed this Year
5.6.2 hRPCs for the Treatment of Retinitis Pigmentosa: In Late Preclinical Development, Will Begin Clinical Trials Soon
5.6.3 Exosome Technology Platform
5.6.4 Non-therapeutic Products: ReNcell VM and ReNcell CX, Licensed to Merck Millipore
5.6.5 Recent Developments in the Company
5.6.6 ReNeuron Revenue, 2011-2014
5.6.7 ReNeuron Outlook in Summary: Underlying Platform a Major Strength and Source of Competitive Advantage
6. Leading Israeli Stem Cell Technology Companies
6.1 Israel: A Strong Presence in Stem Cell Research
6.2 Gamida Cell
6.2.1 Novartis Buys 15% Equity, Likely to Acquire Fully in 2015, other Investors Include Elbit
6.2.2 NAM Technology Platform
6.2.3 Copper Chelator Based Technology
6.2.4 StemEx Shows Improved Survival at 100 Days, and Other Developments
6.2.5 NiCord – Aiming for a “Paradigm Shift” in Treatment Practice, Receives Orphan Drug Designation
6.2.6 Gamida Cell: Outlook in Summary
6.3 Cell Cure Neurosciences
6.3.1 Using Retinal Pigmented Epithelial Cells to Treat AMD, a Disease Affecting More Than 9 Million People in US
6.3.2 OpRegen and OpRegen Plus: Product Candidates for Dry AMD
6.3.3 Exclusive Licence Agreement with Teva for OpRegen and Possibly OpRegen Plus
6.3.4 Cell Cure Neurosciences: Outlook in Summary
6.4 Pluristem Therapeutics
6.4.1 PLX Cells: Secretes Therapeutic Proteins in Damaged Tissues
6.4.2 PLX-PAD for IC in Phase 2 and for CLI in Phase 1
6.4.3 PLX-PAD for Injured Gluteal Muscle in Phase 1/2 and for PAH in Phase 1
6.4.4 PLX-R18 for ARS, in Preclinical Development
6.4.5 Partnerships with United Therapeutics and CHA Bio & Disotech
6.4.6 Pluristem Therapeutics Revenue, 2012-2014
6.4.7 Pluristem Therapeutics Outlook in Summary: Proprietary Technology and PLX-PAD for Multiple Indications
7. Qualitative Analysis of the Stem Cell Technologies Market, 2015-2025
7.1 SWOT Analysis of the Stem Cell Technologies Market
7.2 Strengths
7.2.1 Recent Approvals of Stem Cell Therapies
7.2.2 Relaxation of Regulatory Barriers
7.2.3 Huge Number of Ongoing Clinical Trials – Should Lead to a Barrage of Approvals over the Coming Years
7.2.4 HSCT is Already an Established Procedure
7.3 Weaknesses
7.3.1 Phase 3 Trials Comprise Only a Small Fraction of Present Studies
7.3.2 Regulatory and Reimbursement Concerns
7.3.3 Uncertain Mechanism of Action in Some Stem Cell Therapies
7.4 Opportunities
7.4.1 Unmet Clinical Needs
7.4.2 Interactions with Related Technologies
7.4.3 Non-Therapeutic Uses: Cord Blood Banking and Cell-Based Assays
7.5 Threats
7.5.1 Financial Risks
7.5.2 Pipeline Failure
7.5.3 Long-term Safety Concerns
7.6 STEP Analysis of the Stem Cell Technologies Market
7.7 Social Factors
7.7.1 Increasing Burden of Disease
7.7.2 Biological Insurance through Stem Cell Banking
7.7.3 Stem Cell Tourism: Opportunities and Threats to the Market
7.8 Technological Factors
7.8.1 Increasing Research Output
7.8.2 IPSC Breakthroughs
7.8.3 Greater Understanding of Stem Cell Differentiation
7.8.4 Biomaterials, Bioprinting and Other Developments
7.8.5 CRISPRS: A Breakthrough in Genome Editing
7.9 Economic Factors
7.9.1 Grey Market for Stem Cell Therapies
7.9.2 Broad Changes in Healthcare Markets
7.9.3 New Business Models need to be Developed
7.10 Political Factors
7.10.1 Controversies and Ethical Objections over Embryonic Stem Cell Research
7.10.2 Strong Support from Some Governments
7.10.3 Pressure to Deregulate the Stem Cell Therapies Market
8. Research Interviews
8.1 Interview with Michael Hunt, Chief Financial Officer, ReNeuron
8.1.1 On the Current Status of ReNeuron’s Pipeline, and Thoughts on Expected Launch Dates and Revenues
8.1.2 ReNeuron’s Development in the Future, Its Biggest Strengths and Challenges and Thoughts on an Acquisition
8.1.3 On the Need for New Frameworks for Therapies and the Progress of the UK Government and Agencies in this Regard
8.1.4 On the Controversies Surrounding Stem Cells, the Global Stem Cell Industry, and Key Trends over the Next Ten Years
8.2 Interview with Steve Choi, Head of Investor Relations, MEDIPOST
8.2.1 On MEDIPOST’s Future and its Biggest Strengths, Opportunities and Challenges
8.2.2 On the Status and Development of its Products and Pipeline
8.2.3 On Competition and the South Korean Market in Relation to the World
8.3 Interview with Stefanos Theoharis, Chief Business Officer, Apceth
8.3.1 Apceth’s Current Aims, and its Development over the Next Ten Years
8.3.2 Apceth’s Greatest Strengths, Opportunities and Challenges
8.3.3 Current Status of the Pipeline, Competition, and Variations Among Markets Around the World
8.3.4 How the Stem Cell Industry Needs to Improve over the next Ten Years
8.4 Interview with Karine Kleinhaus, Divisional Vice President, North America, Pluristem
8.4.1 On Pluristem’s Development over the Next Ten Years
8.4.2 On Pluristem’s Greatest Strengths, Opportunities and Challenges
8.4.3 On the Status of Pluristem’s Pipeline and Results from Clinical Trials
8.4.4 On the Stem Cell Industry in the Next Ten Years
8.5 Interview with Yael Margolin, CEO, Gamida Cell
8.5.1 On the Market Potential of Stem Cell Therapy
8.5.2 On NiCord’s Therapeutic Potential and the Patients Being Targeted
8.5.3 On Immune Rejection, Advantages of Using Stem Cells and how NiCord Compares to Other Products in Clinical Development
8.5.4 Partnership with Teva, the Market Environment and Biggest Threats Facing the Industry
8.6 Interview with Robin Smith, Former CEO of NeoStem
8.6.1 On Whether Stem Cell Therapy can Revolutionise Medicine, as has been Suggested
8.6.2 Advantages of NeoStem’s VSEL Technology, and Target Indications for the Company’s Lead Product Candidate
8.6.3 NeoStem as part of Deloitte’s Technology Fast 500
8.6.4 The Issue of High Prices for Stem Cell Therapies and the Biggest Threats to the Stem Cell Market in the Next Decade
8.6.5 Diseases Generating the Most Interest for Stem Cell Treatment
9. Conclusions
9.1 The US Leads the Field for Stem Cell Research
9.2 Market Remains Under Capitalised, in Need of Financing
9.3 Industry has Many Barriers to Overcome
9.4 Competition Will Increase from 2015 to 2025
9.5 Concluding Remarks
【レポート販売概要】
■ タイトル：世界における主要な幹細胞技術企業分析2015-2025■ 英文：Pharma Leader Series: Top Stem Cell Technology Companies 2015-2025
■ 発行日：2015年3月
■ 調査会社：visiongain
■ 商品コード：VGAIN5040804
■ 調査対象地域：グローバル
- レーニーニッケルの世界市場Raney Nickel (CAS 7440-02-0) Market Research Report 2013 presents comprehensive data on raney nickel markets globally and regionally (Europe, Asia, North America etc.) The Raney Nickel (CAS 7440-02-0) Market Research Report 2013 includes raney nickel description, covers its application areas and related patterns. It overviews raney nickel market, names raney nickel producers and indicates its supp …
- 防爆性照明に利用されるLEDランプのグローバル市場(2013-2020)This is the ElectroniCast analysis and forecast of global market consumption of LED-based lamps, which are used in explosion-proof lighting fixtures. Working environments that contain explosive gases or dust are extremely volatile environments. All it takes is a single spark to cause an explosion. A variety of lights are available that are considered explosion proof lighting because they prevent a …
- IoT（モノのインターネット）OS（オペレーティングシステム）の世界市場予測（～2022年）The IoT operating systems market is estimated to grow at a CAGR of 42.9% and expected to grow from USD 289.2 Million in 2017 to USD 1,721.3 Million by 2022, owing to the increase in social networking sites, which has led to sharing of large amounts of personal and private data across multiple platforms. There is an increased need for solutions to make sure that the personal and private data of ind …
- グローバルにおけるシステム・インフラ・ソフトウェア市場（2014-2018）About Global Infrastructure Software System infrastructure software is defined as all the software solutions that help in increasing the performance of IT systems installed in or used by any organization. It helps an organization to perform basic tasks and supports the workflow of its business. These software packages do not perform activities directly related to the business but are essential for …
- 原子力発電所廃炉の世界市場 ：沸騰水型原子炉（BWR）、圧力容器型重水炉（PHWR）、加圧水型原子炉 (PWR)About Nuclear Decommissioning Nuclear decommissioning is the process of dismantling a nuclear facility permanently. The nuclear decommissioning process commences once the owner decides to permanently close down the nuclear facility. It involves the removal of used nuclear fuel from the reactor, cleaning, dismantling, and disposing of all the radioactive components. The decommissioning process is c …
- 自動旅客カウント（APC）及び旅客情報システム（PIS）の世界市場APCs are increasingly used as an alternative to manual passenger counting in North America and Europe to generate and study the ridership trends and patterns. Trains are an important mode of public transport in these region and most APC systems installed in trains are a part of a larger ITS solution. Many new rail vehicles in the region come with an integrated APC system, which is a part of a comp …
- 世界の神経診断装置開発動向：医療機器パイプライン分析2015Neurological Diagnostic Equipment - Medical Devices Pipeline Assessment, 2015 Summary GlobalData's Medical Devices sector report, “Neurological Diagnostic Equipment - Medical Devices Pipeline Assessment, 2015" provides an overview of Neurological Diagnostic Equipment currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the …
- 世界の（医療用）輸液ポンプ及び付属品市場予測（～2018）Infusion pumps and accessories have evolved from regular pumps to modern, automated, integrated, and flexible pumps to meet patient compliance requirements and also provide cost-effective treatment. The safety and quality of infusion pumps and accessories have also gained greater importance in the healthcare market over the years. In this report, the global infusion pump and accessories market is …
- 世界の焼却炉市場：Global Incinerator Market 2014-2018TechNavio's analysts forecast the Global Incinerator market to grow at a CAGR of 5.54 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in waste generation. The Global Incinerator market has also been witnessing the upgrading of existing incinerator technology. However, the increasing number of waste recycling techniques could pose a chall …
- 世界の藻類バイオ燃料技術に関する市場：Global Algae Biofuel Technologies Market 2014-2018TechNavio forecasts The Global Algae Biofuel Technologies Market 2014-2018 with a CAGR of 43.4 percent for the period 2013-2018. Several driving factors and trends will contribute to this growth-all of which will be outlined with detail in this report. TechNavio’s analysts use a unique methodology to scrutinize individual vendor performance, trends, drivers and challenges, and a number of other fa …
- 輸送分野向けバイオメトリクス（生体認証）ソリューションの世界市場About Biometrics Biometrics helps identify individuals on the basis of their physical or behavioral features. It involves verification and identification of physiological traits such as fingerprints, face recognition, DNA, palm print, hand geometry, and iris recognition, and behavioral traits such as keystroke patterns, and speech pattern/voice recognition. An identification system helps determine …
- BRIC（ブラジル/ロシア/インド/中国）の内視鏡検査可視化システム市場BRIC Endoscopy Visualization Systems Market Outlook to 2020 Summary GlobalData’s new report, "BRIC Endoscopy Visualization Systems Market Outlook to 2020", provides key market data on the BRIC Endoscopy Visualization Systems market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - High-End Endoscopy Visualization Sy …
- コネクテッドホームセキュリティシステムの世界市場2017-2021ABSTRACTAbout Connected Home Security System A smart home comprises of an internal network, home automation, and intelligent controls. It is generally defined as a home that is equipped with advanced and automated digital devices, home appliances, and equipment that are interconnected to each other facilitating sophisticated monitoring and control over the building's functions. It performs three d …
- 自動車用エアバッグの世界市場2016-2020：カーテンエアバッグ、フロントエアバッグAbout Automotive Airbag Airbags are automotive safety features in vehicles that are engineered to inflate at a rapid speed during the event of an accident or crash. The inflated airbags help in protecting the in-vehicle occupants in such occurrences. Therefore, these devices are categorized under automotive passive safety features. There are various types of airbags based on their application in v …
- 低温硬化型粉体塗装の世界市場予測（～2023年）Growth of end-use industries is increasing consumption of low temperature powder coatings. The low temperature powder coatings market size is expected to grow from USD 3.9 billion in 2018 to USD 5.2 billion by 2023, at a CAGR of 6.0% during the forecast period. The low temperature powder coatings market is driven by increase in energy savings due to reduction in cure temperatures, growing end-use …
